Dividend stocks can be great income-producing investments, but chasing high yields can sometimes leave you exposed to considerable risk.Did you know that if you have a reliable income stock that yields 6%, you would only need to invest about $16,700 in it to collect $1,000 in dividends over the course of a full year? The average stock on the S&P 500, meanwhile, yields just 1.2%, and it would take an investment of more than $83,000 to generate that same level of dividend income.That's a big part of why high- ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. If Big Pharma was a boy’s club before, now it’s even more so. GSK announced this week that CEO Emma Walmsley is stepping down and handing the reins to the company’s chief commercial officer Luke Miels by the end of the year. The shift brings GSK into what Walmsley described as a “pivotal year.” Walmsley, a former executive from L’Oreal, shifted to the drug industry ...

Key Points Pfizer stock offers a yield above 6% at recent prices. MPLX LP is a pipeline operator that offers a yield above 7% at the moment. Pfizer and MPLX LP could continue raising their dividend payouts for many years to come. 10 stocks we like better than Pfizer › Does the government shutdown have you feeling queasy about investing in stocks? It's understandable, but history says your portfolio's going to be just fine. The last government shutdown, in 2019, is hardly noticeable on a chart of ...

The pharma giant just eliminated two big risks.The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald Trump's intention to lower drug prices and slap a tariff on pharma imports. These two efforts could weigh significantly on these companies' earnings -- and uncertainty about when and how they would be rolled out prompted investors to think twice about buying shares of drug ...

Ah, the stock market. That bastion of rational exuberance, where every tick reflects a careful calculus of earnings, growth, and geopolitical stability. Or, in the era of Donald J. Trump, a frantic scramble to decipher the latest pronouncement from Truth Social. The past few days, particularly the opening salvo of October 2025, have offered a masterclass in market volatility, policy paradoxes, and the sheer audacity of an administration that treats global trade like a high-stakes game of Monopoly, albeit wi ...

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3 Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecen ...

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3 Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecen ...

Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for the disease in ...

FDA监管行动 - 2025年9月FDA向从事GLP-1类药物司美格鲁肽与替尔泊肽配制或制造的企业发出50余封警告信，大部分发布于9月9日 [4] - 警告信主要针对企业网站与宣传材料中被认定为虚假或具有误导性的表述，例如宣称配制制剂是“仿制版本”或含有“相同活性成分” [4] - FDA强调其不对配制药品的安全性、有效性或质量进行评估，且这类药品与FDA已批准的版本并不相同 [4] 警告信具体内容与要求 - FDA就企业声称其产品在减重方面“安全有效”的表述发出警告，包括宣称能够带来“真实效果”或“经证实的有效性” [6] - 警告信不仅寄往配制药企业，持有FDA批准的品牌原研企业也因一档黄金时段电视专题节目收到警告，FDA认为该节目“对其产品安全性造成了误导性印象” [6] - 收到警告信的公司需在15个工作日内作出回应，提交纠正行动计划或合理说明，未能解决违规问题可能面临产品扣押或禁令等执法行动 [6] 行业背景与影响 - FDA的行动发生在GLP-1疗法用于肥胖与2型糖尿病治疗需求飙升，配制药企业介入满足需求之际 [6] - 警告意味着从事GLP-1药品配制的公司需要重新评估标签、广告与推广策略 [6] - FDA信件表明任何暗示与已批准药品等效的表述——无论是直接还是隐含——都可能受到执法 [6]

股票表现与前景 - 自上次分析以来 礼来公司股价已上涨9% [1] - 预计更广泛的医疗保健行业势头将在2026年增强 [1] - 当前仍被视为一个理想的入场点 [1] 分析师持仓披露 - 分析师通过股票所有权、期权或其他衍生品对礼来公司持有有益的多头头寸 [2]